Advertisement
Advertisement

Aytu BioPharma price target lowered to $7 from $9 at Maxim

Maxim lowered the firm’s price target on Aytu BioPharma (AYTU) to $7 from $9 and keeps a Buy rating on the shares.

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1